Company / Cash & Equivalents
SELLAS Life Sciences Group, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$13.9M
FY2024
5-year range
$2.5M / $35.3M
FY2020-FY2024
Trend
+448.9%
vs FY2023
Sector context
#203 of 207
Health Care
What the data says
Cash & Equivalents changed +449% YoY in FY2024, a notable deviation from the 9-year average annual change of +125%.
Based on SEC 10-K filings.
$14M in FY2024 with a 5-year CAGR of +13.8%.
Declined from $17M to $14M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -13.4%
- 5-Year CAGR
- +13.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 207This company $13.9M Sector average $669.5M
▼
-97.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.8%, indicating consistent growth.
- In FY2024, cash & equivalents increased 448.9% year-over-year.
- Ranks #203 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $13.9M | +448.9% |
| FY2023 | $2.5M | -85.2% |
| FY2022 | $17.1M | -19.8% |
| FY2021 | $21.4M | -39.5% |
| FY2020 | $35.3M | +385.1% |
| FY2019 | $7.3M | +36.4% |
| FY2018 | $5.3M | +130.1% |
| FY2017 | $2.3M | -61.1% |
| FY2016 | $6.0M | +326.8% |
| FY2015 | $1.4M | -94.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026